Artiva Biotherapeutics (ARTV) Expected to Announce Earnings on Wednesday

Artiva Biotherapeutics (NASDAQ:ARTV) is projected to issue its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect Artiva Biotherapeutics to announce earnings of ($0.64) per share for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 13, 2026 at 9:30 AM ET.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). On average, analysts expect Artiva Biotherapeutics to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Artiva Biotherapeutics Price Performance

NASDAQ ARTV opened at $10.10 on Monday. The stock has a market capitalization of $249.64 million, a P/E ratio of -2.85 and a beta of 2.18. The business has a 50 day simple moving average of $9.01 and a 200 day simple moving average of $7.53. Artiva Biotherapeutics has a one year low of $2.22 and a one year high of $14.53.

Insiders Place Their Bets

In other Artiva Biotherapeutics news, Director Ra Capital Management, L.P. acquired 6,510,416 shares of Artiva Biotherapeutics stock in a transaction dated Monday, May 11th. The stock was purchased at an average cost of $11.52 per share, for a total transaction of $74,999,992.32. Following the completion of the acquisition, the director directly owned 15,203,995 shares of the company’s stock, valued at $175,150,022.40. This represents a 74.89% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Corp. Gc bought 1,085,069 shares of the firm’s stock in a transaction dated Monday, May 11th. The shares were acquired at an average cost of $11.52 per share, with a total value of $12,499,994.88. Following the completion of the transaction, the insider owned 4,391,969 shares of the company’s stock, valued at $50,595,482.88. This represents a 32.81% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders acquired 9,907,958 shares of company stock worth $107,688,019 and sold 53,040 shares worth $477,890. 21.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Marshall Wace LLP purchased a new stake in Artiva Biotherapeutics in the 4th quarter valued at $341,000. BNP Paribas Financial Markets boosted its holdings in Artiva Biotherapeutics by 14,463.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock worth $340,000 after acquiring an additional 117,733 shares during the last quarter. Renaissance Technologies LLC grew its stake in shares of Artiva Biotherapeutics by 46.8% in the 4th quarter. Renaissance Technologies LLC now owns 116,200 shares of the company’s stock worth $498,000 after acquiring an additional 37,053 shares in the last quarter. Citadel Advisors LLC grew its stake in shares of Artiva Biotherapeutics by 419.3% in the 3rd quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock worth $2,291,000 after acquiring an additional 644,658 shares in the last quarter. Finally, Jane Street Group LLC purchased a new stake in shares of Artiva Biotherapeutics in the fourth quarter valued at about $174,000.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on ARTV. Needham & Company LLC reaffirmed a “buy” rating and set a $41.00 price objective on shares of Artiva Biotherapeutics in a research report on Monday, June 8th. HC Wainwright increased their target price on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Wedbush raised their price target on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a report on Monday, May 11th. Wall Street Zen downgraded shares of Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, May 17th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, May 26th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Artiva Biotherapeutics has a consensus rating of “Moderate Buy” and an average target price of $39.00.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.